What is the recommended dosage of Spiriva (tiotropium) for an adult with COPD or asthma?

Spiriva Dosage Recommendation

For adults with COPD, use Spiriva HandiHaler 18 mcg once daily; for adults and adolescents ≥12 years with asthma, use Spiriva Respimat 2.5 mcg (two puffs of 1.25 mcg each) once daily. 1

COPD Dosing

The FDA-approved dosage for COPD is 18 mcg once daily via HandiHaler (dry powder inhaler). 1 This dose was selected based on dose-ranging studies showing comparable bronchodilator response at doses from 9 to 36 mcg, with the 18 mcg dose offering optimal safety profile. 2

For Spiriva Respimat in COPD: The approved dose is 5 mcg once daily (two puffs of 2.5 mcg each). 3 Multiple trials demonstrated that Respimat 5 mcg provides bronchodilator efficacy similar to HandiHaler 18 mcg, while lower Respimat doses (1.25 and 2.5 mcg) showed reduced efficacy. 3

Key COPD Dosing Points:

• Administer at the same time each day
• No dose adjustment needed for elderly patients, though anticholinergic side effects (dry mouth, constipation, urinary tract infections) increase with age 1
• Contraindicated in patients with narrow-angle glaucoma or symptomatic prostatic hypertrophy/bladder outlet obstruction 1

Asthma Dosing

For asthma in patients ≥12 years: Use Spiriva Respimat 2.5 mcg once daily (two puffs of 1.25 mcg each). 4, 5

This represents a critical distinction: asthma requires HALF the COPD dose when using Respimat. 6 FDA trials demonstrated that the 2.5 mcg dose actually produced better overall pulmonary function measures than the 5 mcg dose in asthma patients, justifying selection of the lower dose. 6

Asthma Treatment Algorithm:

• Add-on therapy only: Tiotropium is approved as add-on to inhaled corticosteroids (ICS) with or without long-acting β2-agonists (LABAs) 4, 5
• Use in moderate-to-severe asthma inadequately controlled on ICS or ICS/LABA combinations 4
• Provides improvements in lung function and reduces exacerbations independent of eosinophilic phenotype 4
• Efficacy is consistent across all age groups (younger and older adults) 7

Device-Specific Considerations

HandiHaler (dry powder): Requires adequate inspiratory flow; may be challenging for patients with severe airflow limitation

Respimat (soft mist): Generates low-velocity, long-duration aerosol with high fine-particle fraction and marked lung deposition; does NOT require strong inspiratory flow 8

Common Pitfalls to Avoid

1. Do not use the COPD dose (5 mcg Respimat) for asthma - the 2.5 mcg dose is more effective 6
2. Do not combine with other anticholinergics - avoid ipratropium or other LAMAs to prevent additive anticholinergic adverse effects 1
3. Monitor for anticholinergic effects: dry mouth (most common, usually mild), constipation, urinary retention, blurred vision, worsening glaucoma 1
4. Not for acute bronchospasm - this is maintenance therapy only 1

Safety Profile

Most common adverse reaction is dry mouth (16% vs 3% placebo), typically mild and often resolves with continued treatment. 1 Other anticholinergic effects include constipation, tachycardia, blurred vision, dysuria, and urinary retention. 1 The safety profile in asthma is similar to placebo. 5